Obesity is significant factor for cancer development in women
the ONA take:
Risk of developing a weight-related cancer is increased for obese women by approximately 40% compared with the risk for women of a healthy weight, according to new statistics released by Cancer Research UK.
The seven types of cancer linked to body weight include bowel, postmenopausal breast, gallbladder, uterine, kidney, pancreatic, and esophageal cancers. In the UK, approximately 18,000 women develop cancer due to obesity or overweight each year.
Researchers acknowledge that losing weight can be challenging, and they recommend people start with small changes that increase their activity levels and food consumption.
Lifestyle changes such as smoking cessation, maintaining a healthy weight, eating a healthy diet, and reducing alcohol intake are solid measures each person can take to reduce their risk of developing cancer.
Risk of developing a weight-related cancer is increased for obese women.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|